安科生物参股公司PA3-17注射液纳入拟突破性治疗品种

Core Viewpoint - Anke Bio (300009) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have developed PA3-17 injection, which has been included in the list of proposed breakthrough therapies by the National Medical Products Administration (NMPA) [1] Group 1 - PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product that has received clinical trial approval for treating adult relapsed/refractory T-lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) [1]